.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Optimizing Outcomes in Tenosynovial Giant Cell Tumors

EP. 1: Overview of Tenosynovial Giant Cell Tumors

May 8th 2020

EP. 2: Review of TSGCT Subtypes: Diffuse Vs Localized Disease

May 8th 2020

EP. 3: Optimal Clinical Workup for Tenosynovial Giant Cell Tumors

May 8th 2020

EP. 4: TSGCT: Establishing a Differential Diagnosis

May 8th 2020

EP. 5: TSGCT: Impacts of Delay in Diagnosis or Misdiagnosis

May 8th 2020

EP. 6: What is the Role of Surgery in TSGCT?

May 8th 2020

EP. 7: TSGCT: Considering Scale of Surgery and Disease Factors

May 8th 2020

EP. 8: Local Recurrence in Tenosynovial Giant Cell Tumors

May 8th 2020

EP. 9: Considerations for Radiation Therapy in TSGCT

May 8th 2020

EP. 10: Tenosynovial Giant Cell Tumors: Symptom and Pain Management

May 8th 2020

EP. 11: Targeting CSF1 in Advanced TSGCT

May 8th 2020

EP. 12: CSF1 Inhibition in TSGCT: Managing Adverse Events

May 8th 2020

EP. 13: Physicians’ Experiences With CSF1 Inhibition in TSGCT

May 8th 2020

EP. 14: TSGCT: Novel Agents and Future Directions in Care

May 8th 2020